Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.52IPCO.TO -0.15DC.A.TO 0.3NESN-SIX 0MCK 13.94GOOG -1.34XLV 0.79TEVA 0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.45
+0.48 (1.70%)
as of Aug 25, 2026, 5:51:24 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
PAST TOP PICK

Pfizer Inc(PFE)

Jun 05, 2003
(Was a top pick on Sept 18/02. Up 10%.) Still likes. Thought they would have been higher. Have the most new products coming on line.
Photo of Rob CallanderRob CallanderUnlock Rating
$32.75

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 30, 2003
Has been stuck under a major technical resistance of $33/34. Could have a drop.
Photo of Ross HealyRoss HealyUnlock Rating
$31.02

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 21, 2003
(Was a top pick on Apr 16/03. Not much change.) Still likes. Continuing to buy at this price.
Photo of Laura WallaceLaura WallaceUnlock Rating
$31.50

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 14, 2003
(Was a top pick on Mar 31/03. Up 6.8%) Still likes. Merger with Pharmacia gives them a very powerful potent drug patent.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$33.21

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Apr 30, 2003
Questioner: "Why is it stuck in a $30/31 range?" Response: "Likes at this price. Their drugs and pipeline are good. Has a lot of cash."
Photo of Paul O'NeilPaul O'NeilUnlock Rating
$30.75

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 22, 2003
A favourite drug stock in their funds. Earnings growth should be 15% over the next several years. Dividend yield is decent. Has a very good pipeline of drugs.
Photo of Brad WillockBrad WillockUnlock Rating
$31.82

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 16, 2003
Just completed a good merger with Pharmacia. Good pipeline.
Photo of Laura WallaceLaura WallaceUnlock Rating
$31.36

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 31, 2003
Just got approval on new products and should move up.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$31.16

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 24, 2003
More expensive in the drug sector. Merk is a better buy.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$30.99

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 06, 2003
Pretty good value. The merger will allow some cost cutting. A good price.
Photo of Ray SteeleRay SteeleUnlock Rating
$29.78

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 04, 2003
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$29.84

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 13, 2003
Well run and strong management. Has grown so big that future growth is difficult.
Photo of Neil MurdockNeil MurdockUnlock Rating
$30.90

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 27, 2002
Not doing much, but a good stock to own.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$29.79

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 16, 2002
Likes the pharmaceutical group. Acquisition of Pharmacia is positive.
Photo of David BurrowsDavid BurrowsUnlock Rating
$31.05

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 12, 2002
Likes. Great value.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$31.12

Stock price when the opinion was issued

$28.42

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 781 to 795 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.87$101
TFPM 0$
OGC.TO -0.31$42.91
SLB -0.3$53.7
ARG.TO 0.39$8.61

Today's Top Picks

SII.TO 3.52$190.71
IPCO.TO -0.15$35.07
DC.A.TO 0.3$5.45
NESN-SIX 0$
MCK 13.94$887.73

Popular Articles

Latest Sell Signals

RKLB -1.15$67.13
INTC 0.47$87.73
MSFT 2.5$489.81
WSP.TO -2.54$189.74
CLS.TO 7.17$414.53

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like